Ribose-Nucleic Acid (RNA)-Based Therapeutics Global Market Report 2024

Description

RNA-based therapeutics are a category of medical treatments that use ribonucleic acid (RNA) molecules to affect cellular functions, often by targeting specific genetic sequences. These therapies aim to address a range of conditions, such as genetic disorders, cancers, and infectious diseases, by altering gene expression, protein production, or cellular signaling pathways.

The primary types of RNA-based therapeutics are RNA interference (RNAi) and RNA antisense. RNA interference (RNAi) is a natural process where RNA molecules suppress gene expression or translation by targeting and neutralizing specific mRNA molecules. These technologies are employed across various therapeutic areas, including oncology, genetic disorders, ophthalmology, hematological disorders, and acute hepatic porphyria (AHP). They are utilized by different users, such as research institutions, hospitals, and clinics.

The ribose-nucleic acid (RNA)-based therapeutics market research report is one of a series of new reports from The Business Research Company that provides ribose-nucleic acid (RNA)-based therapeutics market statistics, including ribose-nucleic acid (RNA)-based therapeutics industry global market size, regional shares, competitors with a ribose-nucleic acid (RNA)-based therapeutics market share, detailed ribose-nucleic acid (RNA)-based therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the ribose-nucleic acid (RNA)-based therapeutics industry. This ribose-nucleic acid (RNA)-based therapeutics market research report delivers a complete perspective on everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The ribose-nucleic acid (RNA)-based therapeutics market size has grown strongly in recent years. It will grow from $14.54 billion in 2023 to $15.79 billion in 2024 at a compound annual growth rate (CAGR) of 8.6%. The increase during the historic period can be attributed to several factors, including rising investments and funding, the breakthrough discovery of RNA interference (RNAi), the clinical success of antisense oligonucleotides (ASOs), supportive regulatory frameworks, and various collaborations and partnerships.

The ribose-nucleic acid (RNA)-based therapeutics market size is expected to see strong growth in the next few years. It will grow to $22.30 billion in 2028 at a compound annual growth rate (CAGR) of 9.0%. The anticipated growth in the forecast period is driven by the broadening of indications, increased market demand and adoption, supportive regulatory measures, the integration of AI and machine learning, and new applications in rare diseases. Key trends for the forecast period include the development of advanced delivery systems, multi-target RNA therapeutics, personalized RNA therapies, regulatory progress, and overall commercialization and market expansion.

The rising incidence of cancer is anticipated to drive the growth of the ribonucleic acid (RNA)-based therapeutics market. Cancer, characterized by the uncontrolled growth and spread of abnormal cells, can be fatal if not treated. Factors contributing to the increasing cancer prevalence include an aging population, lifestyle changes, greater exposure to risk factors, and improved detection techniques. RNA-based therapeutics present a promising treatment option by targeting the genetic and molecular mechanisms involved in cancer. For example, data from the Australian Institute of Health and Welfare reveals that approximately 151,000 people were diagnosed with cancer in 2021 (excluding basal cell and squamous cell skin cancers), with numbers expected to reach 185,000 by 2030. This rising prevalence is driving the RNA-based therapeutics market.

Leading companies in the RNA-based therapeutics market are concentrating on developing novel medication solutions, including messenger RNA (mRNA)-based booster vaccines. These vaccines aim to improve immunization effectiveness, address new viral variants, and enhance the durability of vaccine-induced immunity. An mRNA-based booster vaccine prompts cells to produce a protein that strengthens the immune response against a specific pathogen. For instance, in June 2023, Gennova Biopharmaceuticals Ltd., an Indian pharmaceutical firm, introduced GEMCOVAC-OM, India's first mRNA booster vaccine targeting the Omicron variant of COVID-19. This booster is crucial due to the limited efficacy of earlier vaccines against Omicron, with GEMCOVAC-OM utilizing mRNA technology to enhance immunity and provide better protection against the evolving virus.

In May 2024, Orna Therapeutics, a US-based biotech firm specializing in RNA-based therapeutics, acquired ReNAgade Therapeutics for an undisclosed sum. This acquisition aims to strengthen Orna's position in the industry by integrating its circular RNA expression technology with ReNAgade's advanced lipid nanoparticle (LNP)-based RNA delivery systems and editing programs. ReNAgade Therapeutics, also based in the US, focuses on RNA-based therapeutic solutions.

Major companies operating in the ribose-nucleic acid (RNA)-based therapeutics market are F. Hoffmann-La Roche AG, Eli Lilly and Company, Novo Nordisk A/S, Regeneron Pharmaceuticals, Biogen Inc., Houston Methodist Hospital, BioNTech, University of Oxford, Alnylam Pharmaceuticals, Sarepta Therapeutics, Flagship Pioneering, Ionis Pharmaceuticals, Akcea Therapeutics Inc, Arrowhead Pharmaceuticals, Dicerna Pharmaceuticals, Wave Life Sciences, Pharmaceutical Technology, Quark Pharmaceuticals, Tekmira Pharmaceuticals, ReCode Therapeutics, Arbutus Biopharma Corporation, Benitec Biopharma Inc., Olix Pharmaceuticals, Alltrna Inc., Orbital Therapeutics

North America was the largest region in the ribose-nucleic acid (RNA)-based therapeutics market in 2023. The regions covered in the ribose-nucleic acid (RNA)-based therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the ribose-nucleic acid (RNA)-based therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The ribose-nucleic acid (RNA)-based therapeutics market consists of revenues earned by entities by custom synthesis of RNA, RNA delivery systems, and RNA sequencing analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. The ribose-nucleic acid (RNA)-based therapeutics market also include the sale of microRNA (miRNA) therapeutics, antisense oligonucleotides, and messenger RNA (mRNA) vaccines. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Ribose-Nucleic Acid (RNA)-Based Therapeutics Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on ribose-nucleic acid (RNA)-based therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for ribose-nucleic acid (RNA)-based therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The ribose-nucleic acid (RNA)-based therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Type: RNA Interference (RNAi); RNA Antisense
2) By Technology: Enabling Technology; Enabled Technology
3) By Therapeutic Area: Oncology; Genetic Disorder; Ophthalmology; Hematological Disorders; Acute Hepatic Porphyria (AHP); Other Therapeutic Areas
4) By End User: Research Institutes; Hospitals And Clinics
Companies Mentioned: F. Hoffmann-La Roche AG; Eli Lilly and Company; Novo Nordisk A/S; Regeneron Pharmaceuticals; Biogen Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r19768

1. Executive Summary

2. Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Characteristics

3. Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Trends And Strategies

4. Ribose-Nucleic Acid (RNA)-Based Therapeutics Market - Macro Economic Scenario

4.1. Impact Of High Inflation On The Market
4.2. Ukraine-Russia War Impact On The Market
4.3. COVID-19 Impact On The Market

5. Global Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Size and Growth

5.1. Global Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Ribose-Nucleic Acid (RNA)-Based Therapeutics Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Ribose-Nucleic Acid (RNA)-Based Therapeutics Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Segmentation

6.1. Global Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
RNA Interference (RNAi)
RNA Antisense
6.2. Global Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Enabling Technology
Enabled Technology
6.3. Global Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Oncology
Genetic Disorder
Ophthalmology
Hematological Disorders
Acute Hepatic Porphyria (AHP)
Other Therapeutic Areas
6.4. Global Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Research Institutes
Hospitals And Clinics

7. Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Regional And Country Analysis

7.1. Global Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Ribose-Nucleic Acid (RNA)-Based Therapeutics Market

8.1. Asia-Pacific Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Ribose-Nucleic Acid (RNA)-Based Therapeutics Market

9.1. China Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Overview
9.2. China Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Ribose-Nucleic Acid (RNA)-Based Therapeutics Market

10.1. India Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Ribose-Nucleic Acid (RNA)-Based Therapeutics Market

11.1. Japan Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Overview
11.2. Japan Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Ribose-Nucleic Acid (RNA)-Based Therapeutics Market

12.1. Australia Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Ribose-Nucleic Acid (RNA)-Based Therapeutics Market

13.1. Indonesia Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Ribose-Nucleic Acid (RNA)-Based Therapeutics Market

14.1. South Korea Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Overview
14.2. South Korea Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Ribose-Nucleic Acid (RNA)-Based Therapeutics Market

15.1. Western Europe Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Overview
15.2. Western Europe Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Ribose-Nucleic Acid (RNA)-Based Therapeutics Market

16.1. UK Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Ribose-Nucleic Acid (RNA)-Based Therapeutics Market

17.1. Germany Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Ribose-Nucleic Acid (RNA)-Based Therapeutics Market

18.1. France Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Ribose-Nucleic Acid (RNA)-Based Therapeutics Market

19.1. Italy Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Ribose-Nucleic Acid (RNA)-Based Therapeutics Market

20.1. Spain Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Ribose-Nucleic Acid (RNA)-Based Therapeutics Market

21.1. Eastern Europe Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Overview
21.2. Eastern Europe Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Ribose-Nucleic Acid (RNA)-Based Therapeutics Market

22.1. Russia Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Ribose-Nucleic Acid (RNA)-Based Therapeutics Market

23.1. North America Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Overview
23.2. North America Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Ribose-Nucleic Acid (RNA)-Based Therapeutics Market

24.1. USA Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Overview
24.2. USA Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Ribose-Nucleic Acid (RNA)-Based Therapeutics Market

25.1. Canada Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Overview
25.2. Canada Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Ribose-Nucleic Acid (RNA)-Based Therapeutics Market

26.1. South America Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Overview
26.2. South America Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Ribose-Nucleic Acid (RNA)-Based Therapeutics Market

27.1. Brazil Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Ribose-Nucleic Acid (RNA)-Based Therapeutics Market

28.1. Middle East Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Overview
28.2. Middle East Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Ribose-Nucleic Acid (RNA)-Based Therapeutics Market

29.1. Africa Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Overview
29.2. Africa Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Competitive Landscape And Company Profiles

30.1. Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Competitive Landscape
30.2. Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Company Profiles
- 30.2.1. F. Hoffmann-La Roche AG
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. Eli Lilly and Company
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. Novo Nordisk A/S
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. Regeneron Pharmaceuticals
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. Biogen Inc.
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Other Major And Innovative Companies

31.1. Houston Methodist Hospital
31.2. BioNTech
31.3. University of Oxford
31.4. Alnylam Pharmaceuticals
31.5. Sarepta Therapeutics
31.6. Flagship Pioneering
31.7. Ionis Pharmaceuticals
31.8. Akcea Therapeutics Inc
31.9. Arrowhead Pharmaceuticals
31.10. Dicerna Pharmaceuticals
31.11. Wave Life Sciences
31.12. Pharmaceutical Technology
31.13. Quark Pharmaceuticals
31.14. Tekmira Pharmaceuticals
31.15. ReCode Therapeutics

32. Global Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Competitive Benchmarking

33. Global Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Ribose-Nucleic Acid (RNA)-Based Therapeutics Market

35. Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Future Outlook and Potential Analysis

35.1 Ribose-Nucleic Acid (RNA)-Based Therapeutics Market In 2028 - Countries Offering Most New Opportunities
35.2 Ribose-Nucleic Acid (RNA)-Based Therapeutics Market In 2028 - Segments Offering Most New Opportunities
35.3 Ribose-Nucleic Acid (RNA)-Based Therapeutics Market In 2028 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer